ATE446303T1 - Agonisten und antagonisten von sphingosin-1- phosphatrezeptoren - Google Patents

Agonisten und antagonisten von sphingosin-1- phosphatrezeptoren

Info

Publication number: ATE446303T1
Authority: AT; Austria
Prior art keywords: sub; sphingosine; agonists; antagonists; alkenyl
Prior art date: 2001-01-30

Application number

AT02704296T

Other languages

English (en)

Inventor

Timothy Macdonald

Kevin Lynch

Original Assignee

Univ Virginia

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2001-01-30

Filing date

2002-01-30

Publication date

2009-11-15

2002-01-30 Application filed by Univ Virginia filed Critical Univ Virginia

2009-11-15 Application granted granted Critical

2009-11-15 Publication of ATE446303T1 publication Critical patent/ATE446303T1/de

Links

102000011011 Sphingosine 1-phosphate receptors Human genes 0.000 title abstract 3
108050001083 Sphingosine 1-phosphate receptors Proteins 0.000 title abstract 3
239000000556 agonist Substances 0.000 title 1
239000005557 antagonist Substances 0.000 title 1
125000003342 alkenyl group Chemical group 0.000 abstract 2
125000000217 alkyl group Chemical group 0.000 abstract 2
150000001875 compounds Chemical class 0.000 abstract 2
TTZMPOZCBFTTPR-UHFFFAOYSA-N O=P1OCO1 Chemical class O=P1OCO1 TTZMPOZCBFTTPR-UHFFFAOYSA-N 0.000 abstract 1
DLWPEEDVEAHLHI-UHFFFAOYSA-N OP(O)=O.O=P1OCO1 Chemical compound OP(O)=O.O=P1OCO1 DLWPEEDVEAHLHI-UHFFFAOYSA-N 0.000 abstract 1
229910019142 PO4 Inorganic materials 0.000 abstract 1
125000002877 alkyl aryl group Chemical group 0.000 abstract 1
239000003795 chemical substances by application Substances 0.000 abstract 1
201000010099 disease Diseases 0.000 abstract 1
208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
125000001072 heteroaryl group Chemical group 0.000 abstract 1
125000002887 hydroxy group Chemical group [H]O* 0.000 abstract 1
NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 abstract 1
239000010452 phosphate Substances 0.000 abstract 1
125000003107 substituted aryl group Chemical group 0.000 abstract 1

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
- C07F9/02—Phosphorus compounds
- C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
- C07F9/645—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having two nitrogen atoms as the only ring hetero atoms
- C07F9/6503—Five-membered rings
- C07F9/6506—Five-membered rings having the nitrogen atoms in positions 1 and 3
- C07F9/65068—Five-membered rings having the nitrogen atoms in positions 1 and 3 condensed with carbocyclic rings or carbocyclic ring systems
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/08—Drugs for disorders of the urinary system of the prostate
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/06—Antimigraine agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A61P29/02—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID] without antiinflammatory effect
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/10—Antimycotics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P33/00—Antiparasitic agents
- A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C237/00—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups
- C07C237/02—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups having the carbon atoms of the carboxamide groups bound to acyclic carbon atoms of the carbon skeleton
- C07C237/04—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups having the carbon atoms of the carboxamide groups bound to acyclic carbon atoms of the carbon skeleton the carbon skeleton being acyclic and saturated
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
- C07F9/02—Phosphorus compounds
- C07F9/06—Phosphorus compounds without P—C bonds
- C07F9/08—Esters of oxyacids of phosphorus
- C07F9/09—Esters of phosphoric acids
- C07F9/091—Esters of phosphoric acids with hydroxyalkyl compounds with further substituents on alkyl
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
- C07F9/02—Phosphorus compounds
- C07F9/28—Phosphorus compounds with one or more P—C bonds
- C07F9/38—Phosphonic acids [RP(=O)(OH)2]; Thiophosphonic acids ; [RP(=X1)(X2H)2(X1, X2 are each independently O, S or Se)]
- C07F9/3804—Phosphonic acids [RP(=O)(OH)2]; Thiophosphonic acids ; [RP(=X1)(X2H)2(X1, X2 are each independently O, S or Se)] not used, see subgroups
- C07F9/3808—Acyclic saturated acids which can have further substituents on alkyl

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Life Sciences & Earth Sciences (AREA)
General Health & Medical Sciences (AREA)
Veterinary Medicine (AREA)
General Chemical & Material Sciences (AREA)
Medicinal Chemistry (AREA)
Pharmacology & Pharmacy (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Animal Behavior & Ethology (AREA)
Chemical Kinetics & Catalysis (AREA)
Public Health (AREA)
Engineering & Computer Science (AREA)
Bioinformatics & Cheminformatics (AREA)
Biomedical Technology (AREA)
Neurosurgery (AREA)
Neurology (AREA)
Molecular Biology (AREA)
Biochemistry (AREA)
Pain & Pain Management (AREA)
Oncology (AREA)
Communicable Diseases (AREA)
Diabetes (AREA)
Pulmonology (AREA)
Psychiatry (AREA)
Virology (AREA)
Immunology (AREA)
Urology & Nephrology (AREA)
Hematology (AREA)
Obesity (AREA)
Tropical Medicine & Parasitology (AREA)
AIDS & HIV (AREA)
Hospice & Palliative Care (AREA)
Emergency Medicine (AREA)
Vascular Medicine (AREA)
Cardiology (AREA)
Heart & Thoracic Surgery (AREA)
Child & Adolescent Psychology (AREA)
Rheumatology (AREA)

AT02704296T 2001-01-30 2002-01-30 Agonisten und antagonisten von sphingosin-1- phosphatrezeptoren ATE446303T1 (de)

Applications Claiming Priority (3)

Application Number	Priority Date	Filing Date	Title
US26492701P	2001-01-30	2001-01-30
US32781401P	2001-10-09	2001-10-09
PCT/US2002/002715 WO2002064616A2 (en)	2001-01-30	2002-01-30	Agonists and antagonists of sphingosine-1-phosphate receptors

Publications (1)

Publication Number	Publication Date
ATE446303T1 true ATE446303T1 (de)	2009-11-15

Family

ID=26950835

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
AT02704296T ATE446303T1 (de)	2001-01-30	2002-01-30	Agonisten und antagonisten von sphingosin-1- phosphatrezeptoren

Country Status (8)

Country	Link
US (1)	US7064217B2 (de)
EP (1)	EP1383778B1 (de)
JP (1)	JP2004529100A (de)
AT (1)	ATE446303T1 (de)
AU (1)	AU2002237988B2 (de)
CA (1)	CA2437358A1 (de)
DE (1)	DE60234092D1 (de)
WO (1)	WO2002064616A2 (de)

Families Citing this family (58)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
EP1424078A4 (de) *	2001-09-04	2009-03-25	Ono Pharmaceutical Co	Mittel zur behandlung von atemwegserkrankungen mit sphingosin-1-phosphat-rezeptor-regler
ITRM20010688A1 (it)	2001-11-21	2003-05-21	Univ Roma	Composti immunoregolatori.
RU2358717C2 (ru) *	2002-05-16	2009-06-20	Новартис Аг	Применение средств, связывающих edg-рецептор, в лечении ракового заболевания
GB0217152D0 (en)	2002-07-24	2002-09-04	Novartis Ag	Organic compounds
US7241790B2 (en) *	2002-07-30	2007-07-10	University Of Virginia Patent Foundation	Compounds active in spinigosine 1-phosphate signaling
JP4571497B2 (ja)	2002-09-19	2010-10-27	杏林製薬株式会社	アミノアルコール誘導体とその付加塩及び免疫抑制剤
BRPI0407658A (pt)	2003-02-18	2006-02-21	Kyorin Seiyaku Kk	derivados de ácido aminofosfÈnico, seus sais e hidratos que atuam como moduladores de receptor de s1p e agente farmacêutico
CL2004001120A1 (es)	2003-05-19	2005-04-15	Irm Llc	Compuestos derivados de amina sustituidas con heterociclos, inmunosupresores; composicion farmaceutica; y uso para tratar enfermedades mediadas por interacciones de linfocito, tales como enfermedades autoinmunes, inflamatorias, infecciosas, cancer.
EP1481680A1 (de) *	2003-05-30	2004-12-01	Aventis Pharma Deutschland GmbH	Verwendung von S1P
US7638637B2 (en)	2003-11-03	2009-12-29	University Of Virginia Patent Foundation	Orally available sphingosine 1-phosphate receptor agonists and antagonists
GB0401332D0 (en) *	2004-01-21	2004-02-25	Novartis Ag	Organic compounds
US7781617B2 (en)	2004-07-16	2010-08-24	Kyorin Pharmaceutical Co., Ltd	Effective use method of medicaments and method of preventing expression of side effect
WO2006014816A2 (en) *	2004-07-27	2006-02-09	Merck & Co., Inc.	Canis sphingosine 1-phosphate receptor isoform 2
MX2007001661A (es)	2004-08-13	2007-04-23	Praecis Pharm Inc	Metodos y composiciones para modular la actividad del receptor de esfingosina -1 fosfato (sip).
US20060223866A1 (en) *	2004-08-13	2006-10-05	Praecis Pharmaceuticals, Inc.	Methods and compositions for modulating sphingosine-1-phosphate (S1P) receptor activity
EP1806338B1 (de) *	2004-10-12	2016-01-20	Kyorin Pharmaceutical Co., Ltd.	Verfahren zur herstellung von 2-amino-2-[2-[4-(3-benzyloxyphenylthio)-2-chlorphenyl[ethyl]-1,3-propandiolhydrochlorid und hydraten davon, und zwischenprodukte in deren herstellung
WO2006063033A2 (en) *	2004-12-06	2006-06-15	University Of Virginia Patent Foundation	Aryl amide sphingosine 1-phosphate analogs
US7754703B2 (en)	2005-02-14	2010-07-13	University Of Virginia Patent Foundation	Cycloalkane-containing sphingosine 1-phosphate agonists
GB0513431D0 (en)	2005-06-30	2005-08-10	Kherion Technology Ltd	Prophylactic compositions and uses
PL1932522T3 (pl) *	2005-10-07	2012-09-28	Kyorin Seiyaku Kk	Środek terapeutyczny do leczenia choroby wątroby zawierający jako składnik czynny pochodną 2-amino-1,3-propanodiolu
US8546452B2 (en)	2005-10-12	2013-10-01	Toa Eiyo Ltd.	S1P3 receptor antagonist
US7919519B2 (en)	2005-11-23	2011-04-05	Epix Pharmaceuticals Inc.	S1P receptor modulating compounds and use thereof
EP1965807A4 (de)	2005-11-23	2010-10-27	Epix Delaware Inc	S1p-rezeptor-modulierende verbindungen und ihre verwendung
JP2009528274A (ja) *	2006-01-27	2009-08-06	ユニバーシティオブバージニアパテントファンデーション	神経因性疼痛の治療法
TWI389683B (zh) *	2006-02-06	2013-03-21	Kyorin Seiyaku Kk	A therapeutic agent for an inflammatory bowel disease or an inflammatory bowel disease treatment using a 2-amino-1,3-propanediol derivative as an active ingredient
JP2009526073A (ja) *	2006-02-09	2009-07-16	ユニバーシティオブバージニアパテントファンデーション	二環式スフィンゴシン−１−リン酸受容体アナログ
AU2007227274A1 (en)	2006-03-21	2007-09-27	Epix Delaware, Inc.	S1P receptor modulating compounds
JP5140593B2 (ja)	2006-08-08	2013-02-06	杏林製薬株式会社	アミノアルコール誘導体及びそれらを有効成分とする免疫抑制剤
CA2659598A1 (en)	2006-08-08	2008-02-14	Kyorin Pharmaceutical Co., Ltd.	Amino phosphate derivative and s1p receptor modulator having same as an active ingredient
JP2010510249A (ja)	2006-11-21	2010-04-02	ユニバーシティオブバージニアパテントファンデーション	スフィンゴシン＝１−燐酸アゴニスト活性を有するテトラリンアナログ
AU2007323557A1 (en) *	2006-11-21	2008-05-29	University Of Virginia Patent Foundation	Benzocycloheptyl analogs having sphingosine 1-phosphate receptor activity
CA2669104A1 (en) *	2006-11-21	2008-05-29	University Of Virginia Patent Foundation	Hydrindane analogs having sphingosine 1-phosphate receptor agonist activity
CA2684953C (en) *	2007-05-04	2016-08-09	Novartis Ag	Use of s1p receptor modulator
CN101358609A (zh) *	2007-08-03	2009-02-04	富准精密工业(深圳)有限公司	风扇转子
AU2008302746B2 (en)	2007-09-20	2014-07-03	Amgen Inc.	1-(4-(benzylbenzamid0) -benzyl) azetidine-3-carboxylic acid derivatives and related compounds as SlP receptor modulators for the treatment of immune disorders
WO2009085847A1 (en)	2008-01-03	2009-07-09	Allergan, Inc.	Tetrahydroindoles having sphingosine-1-phosphate receptor activity
TW200946105A (en) *	2008-02-07	2009-11-16	Kyorin Seiyaku Kk	Therapeutic agent or preventive agent for inflammatory bowel disease containing amino alcohol derivative as active ingredient
US8212010B2 (en) *	2008-02-25	2012-07-03	Expression Drug Designs, Llc	Sphingosine 1-phosphate antagonism
US8580841B2 (en)	2008-07-23	2013-11-12	Arena Pharmaceuticals, Inc.	Substituted 1,2,3,4-tetrahydrocyclopenta[b]indol-3-yl)acetic acid derivatives useful in the treatment of autoimmune and inflammatory disorders
EP2328863A1 (de) *	2008-08-12	2011-06-08	Allergan, Inc.	Antagonisten des sphingosin-1-phosphat-(s1p-)rezeptors und methoden zu deren anwendung
HRP20160890T1 (hr)	2008-08-27	2016-09-23	Arena Pharmaceuticals, Inc.	Derivati supstituirane tricikličke kiseline kao agonisti s1p1-receptora korisni u liječenju autoimunih i upalnih poremećaja
WO2010051030A1 (en)	2008-10-30	2010-05-06	Biogen Idec Ma Inc.	Bicyclic aryl sphingosine 1-phosphate analogs
US9181191B2 (en)	2008-10-30	2015-11-10	Biogen Ma Inc.	Heterobicyclic sphingosine 1-phosphate analogs
EP2364089B1 (de) *	2008-10-30	2016-12-07	Biogen MA Inc.	Heterobicyclische sphingosin-1-phosphatanaloge
WO2011028927A1 (en) *	2009-09-04	2011-03-10	Allergan, Inc.	Selective sphingosine-1-phosphate receptor antagonists
JP5856980B2 (ja)	2010-01-27	2016-02-10	アリーナファーマシューティカルズ，インコーポレイテッド	（Ｒ）−２−（７−（４−シクロペンチル−３−（トリフルオロメチル）ベンジルオキシ）−１，２，３，４−テトラヒドロシクロペンタ［ｂ］インドール−３−イル）酢酸およびその塩の調製のためのプロセス
CN105503882B (zh)	2010-03-03	2019-07-05	艾尼纳制药公司	制备s1p1受体调节剂及其晶体形式的方法
US10106778B2 (en) *	2012-11-08	2018-10-23	Whitehead Institute For Biomedical Research	Selective targeting of cancer stem cells
ES2749467T3 (es) *	2012-11-20	2020-03-20	Biogen Ma Inc	Agentes moduladores de S1p y/o ATX
WO2015168255A1 (en)	2014-04-29	2015-11-05	Whitehead Institute For Biomedical Research	Methods and compositions for targeting cancer stem cells
PL3242666T3 (pl)	2015-01-06	2025-02-17	Arena Pharmaceuticals, Inc.	Związek do zastosowania w leczeniu dolegliwości związanych z receptorem s1p1
BR112017027656B1 (pt)	2015-06-22	2023-12-05	Arena Pharmaceuticals, Inc.	Hábito cristalino de placa livre de sal de l-arginina de ácido (r)-2-(7-(4- ciclopentil-3-(trifluorometil)benzilóxi)- 1,2,3,4-tetra-hidrociclo-penta[b]indol-3- il)acético, composição farmacêutica que o compreende, seus usos e método de preparação do mesmo
MX2019009843A (es)	2017-02-16	2020-01-30	Arena Pharm Inc	Compuestos y metodos para el tratamiento de la enfermedad inflamatoria intestinal con manifestaciones extraintestinales.
MX2019009841A (es)	2017-02-16	2020-01-30	Arena Pharm Inc	Compuestos y metodos para el tratamiento de la colangitis biliar primaria.
IL252151A0 (en)	2017-05-07	2017-07-31	Fainzilber Michael	Treatment of stress disorders
CA3102136A1 (en)	2018-06-06	2019-12-12	Arena Pharmaceuticals, Inc.	Methods of treating conditions related to the s1p1 receptor
CN112955431A (zh)	2018-09-06	2021-06-11	艾尼纳制药公司	可用于治疗自身免疫性病症和炎性病症的化合物
AU2022285344A1 (en)	2021-05-31	2023-12-14	Rena Therapeutics Inc.	Ligand-bound nucleic acid complex

Family Cites Families (23)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US2548155A (en) *	1948-10-02	1951-04-10	Goodrich Co B F	Preparation of amides
US3193458A (en) *	1961-07-12	1965-07-06	Us Vitamin Pharm Corp	Method of lowering blood cholesterol level
US4906767A (en) *	1987-06-30	1990-03-06	The University Of Southern Mississippi	Monomers with urea groups
WO1990002727A1 (fr) *	1988-09-14	1990-03-22	Yoshitomi Pharmaceutical Industries, Ltd.	Immunodepresseur
DE4134156A1 (de)	1991-10-11	1993-04-15	Schering Ag	9-substituierte bicyclo(3.3.0)octan-derivate, verfahren zu ihrer herstellung und ihre pharmazeutische verwendung
DE4225488A1 (de)	1992-07-30	1994-02-03	Schering Ag	Neue Bicyclo[3.3.0]octan-Derivate, Verfahren zu ihrer Herstellung und ihre pharmazeutische Verwendung
DE69321823T2 (de)	1992-10-21	1999-06-02	Taito Co., Ltd., Tokio/Tokyo	2-amino-1, 3- propandiolverbindung und immunosuppressium
IT1271267B (it)	1994-12-14	1997-05-27	Valle Francesco Della	Ammidi di acidi mono e bicarbossilici con amminoalcoli,selettivamente attive sul recettore periferico dei cannabinoidi
US5604988A (en) *	1995-03-30	1997-02-25	Costelloe; Paul M.	Multipurpose device for marking or placing a workpiece
US5773475A (en) *	1997-03-17	1998-06-30	Research Corporation Technologies, Inc.	Anticonvulsant enantiomeric amino acid derivatives
US6069162A (en) *	1996-05-27	2000-05-30	Fujisawa Pharmaceutical Co., Ltd.	Indolyl and benzofuranyl carboxamides as inhibitors of nitric oxide production
ES2240868T3 (es)	1997-04-04	2005-10-16	Mitsubishi Pharma Corporation	Compuesto de 2-aminopropano -1,3-diol, su uso farmaceutico e intermedios en su sintesis.
ATE332888T1 (de) *	1997-09-11	2006-08-15	Takara Bio Inc	Sphingosinderivate und medizinische zubereitung
CN1168702C (zh) *	1998-06-30	2004-09-29	Om药业	酰基-二肽类化合物,其制备方法以及含有前述化合物的药物组合物
WO2001003739A1 (fr)	1999-07-12	2001-01-18	Ono Pharmaceutical Co., Ltd.	Inhibiteurs de fibrose contenant comme ingredient actif l'agoniste du recepteur de sphingosine-1-phosphate ou la sphingosine-1-phosphate
EP1257559A1 (de)	2000-02-07	2002-11-20	Merck & Co., Inc.	Sphingosin-1-phosphat phosphatase von lebewesen
PT1258484E (pt)	2000-02-18	2009-04-03	Kyowa Hakko Kirin Co Ltd	Novos compostos de isoxazol e de tiazol e sua utilização enquanto fármacos
CA2402038C (en)	2000-03-17	2011-03-15	The University Of Tennessee Research Corporation	Lpa receptor agonists and antagonists and methods of use
WO2001098301A1 (en)	2000-06-20	2001-12-27	Japan Tobacco Inc.	Pyrazolopyridine compounds and use thereof as drugs
CN1328387C (zh)	2000-07-13	2007-07-25	三共株式会社	氨基醇衍生物
EP1315735A4 (de)	2000-08-31	2005-04-06	Merck & Co Inc	Phosphat-derivate als immunoregulatorische verbindungen
WO2002018402A2 (en)	2000-09-01	2002-03-07	Neuronyx, Inc.	Novel synthetic gangliosides
WO2003061567A2 (en)	2002-01-18	2003-07-31	Merck & Co., Inc.	Selective s1p1/edg1 receptor agonists

2002
- 2002-01-30 JP JP2002564545A patent/JP2004529100A/ja active Pending
- 2002-01-30 AU AU2002237988A patent/AU2002237988B2/en not_active Ceased
- 2002-01-30 EP EP02704296A patent/EP1383778B1/de not_active Expired - Lifetime
- 2002-01-30 US US10/470,820 patent/US7064217B2/en not_active Expired - Lifetime
- 2002-01-30 AT AT02704296T patent/ATE446303T1/de not_active IP Right Cessation
- 2002-01-30 WO PCT/US2002/002715 patent/WO2002064616A2/en not_active Ceased
- 2002-01-30 DE DE60234092T patent/DE60234092D1/de not_active Expired - Fee Related
- 2002-01-30 CA CA002437358A patent/CA2437358A1/en not_active Abandoned

Also Published As

Publication number	Publication date
DE60234092D1 (de)	2009-12-03
WO2002064616A2 (en)	2002-08-22
EP1383778A4 (de)	2005-03-09
EP1383778B1 (de)	2009-10-21
US7064217B2 (en)	2006-06-20
EP1383778A2 (de)	2004-01-28
JP2004529100A (ja)	2004-09-24
AU2002237988B2 (en)	2008-01-03
WO2002064616A3 (en)	2002-11-14
US20040110728A1 (en)	2004-06-10
CA2437358A1 (en)	2002-08-22

Legal Events

Date	Code	Title	Description
2010-04-15	RER	Ceased as to paragraph 5 lit. 3 law introducing patent treaties

Publication	Publication Date	Title
ATE446303T1 (de)	2009-11-15	Agonisten und antagonisten von sphingosin-1- phosphatrezeptoren
ATE380187T1 (de)	2007-12-15	Agonisten und antagonisten für den lpa-rezeptor und anwendungsmethoden
MY147730A (en)	2013-01-15	Metabotropic glutamate receptor antagonists
DK1628685T3 (da)	2011-03-21	Antivirale phosphonatanaloge
ATE318267T1 (de)	2006-03-15	Einige alkylendiamin-substituierte heterocyclen
WO2005002626A3 (en)	2005-05-26	Therapeutic phosphonate compounds
BRPI0409680A (pt)	2006-04-18	análogos de fosfonato anti-cáncer
ECSP045229A (es)	2004-09-28	Piridinonas sustituidas como moduladores de la p38 map quinasa
DE60220422D1 (de)	2007-07-12	Substituierte pyrazoloverbindungen zur behandlung von entzündungen
NO20055590L (no)	2006-01-24	Kinaseinhiberende fosfonatanaloger
EA200600358A1 (ru)	2006-08-25	Фенил- или пиридиламидные соединения в качестве антагонистов простагландина е2
BE2013C003I2 (de)	2020-08-20
MXPA05010824A (es)	2005-12-05	Compuestos biciclicos como antagonistas del receptor nr2b.
TW200519096A (en)	2005-06-16	Quinazoline analogs as receptor tyrosine kinase inhibitors
DE602004027409D1 (de)	2010-07-08	Tetrahydrofuroä3,4-düdioxolverbindungen und zusammensetzungen und verfahren zur inhibierung der trombozytenaggregation
EA200000336A1 (ru)	2000-10-30	Антагонисты рецептора витронектина
EA200301317A1 (ru)	2004-06-24	Производные аминохинолина и его применение в качестве лигандов аденозина a3
MXPA05011294A (es)	2006-03-15	Compuestos de fosfonato anti-inflamatorios.
PT874841E (pt)	2002-03-28	Derivados da 1-benzenossulfonilpirrolidina como antagonistas do receptor da bradiquinina
BR0311970A (pt)	2005-03-29	Novos compostos, seu uso e preparação
BR9813920A (pt)	2000-09-26	Trifluorometilbifenilil-dihalofenilazolinas como pesticidas
BRPI0414511A (pt)	2006-11-07	composto, composições farmacêuticas, e, uso de um composto
EA200200733A1 (ru)	2002-12-26	Новые гетероарильные производные, их получение и применение
ATE314059T1 (de)	2006-01-15	VERWENDUNG VON ßXYLYLOXY ALKYL AMINESß FÜR DIE BEHANDLUNG VON TINNITUS
MXPA05011287A (es)	2006-01-24	Analogos de fosfonato anti-cancer.